Abstract Background Cyclooxygenase (COX)-2 inhibitors such as celecoxib were designed
to preserve anti-inflammatory activity without inhibiting COX-1. Downregulation of COX-2 …

Abstract The Adenoma Prevention with Celecoxib Trial examined the efficacy and safety of
the cyclooxygenase (Cox)-2 inhibitor, celecoxib, for sporadic colorectal adenoma prevention …

COX inhibitors reduce colorectal adenoma recurrence by up to 45% and selenium
supplementation may prevent colorectal cancer. Following colonoscopic adenoma …

Background Studies showing that drugs that inhibit cyclooxygenase-2 (COX-2) reduce the
number of colorectal adenomas in animals and patients with familial adenomatous …

Background Overexpression of cyclooxygenase 2 (COX-2) has been associated with
colorectal adenomatous polyps and cancer, prompting researchers to propose its inhibition …

Background—Cyclooxygenase-2 (COX-2) inhibitors have been shown to reduce colorectal
adenomas but have been associated with increased cardiovascular risk. Methods and …

Background Celecoxib has previously been shown to be effective in reducing recurrent
colorectal adenomas, but its long-term effects are unknown. In addition, safety issues are of …

Conclusive findings of cardiovascular (CV) toxicity associated with nonsteroidal anti-
inflammatory drugs (NSAID) in two major colorectal-adenoma prevention trials (1, 2) …

Background Selective cyclooxygenase-2 (COX-2) inhibitors have come under scrutiny
because of reports suggesting an increased cardiovascular risk associated with their use …

Reason for posting: Coxibs, the class of NSAIDs that selectively inhibit cyclooxygenase 2
(COX-2), were designed to reduce joint pain and inflammation without causing the gastric …